First inter-institutional consensus on Chronic Myeloproliferative Neoplasms
Gilberto Barranco-Lampón1,2, Raúl Martínez-Castro3, Luara Arana-Luna4
1Servicio de Hematología, Hospital General de México, Ciudad de México, México.
Gaceta Medica De Mexico
|September 21, 2023
Summary
This consensus provides updated diagnostic and treatment information for chronic myeloproliferative neoplasms (MPNs) to Mexican healthcare professionals. It aims to unify clinical practice and improve patient care nationwide.
Area of Science:
- Hematology
- Oncology
- Public Health
Background:
- Chronic myeloproliferative neoplasms (MPNs) require standardized diagnostic and treatment protocols.
- Varied clinical practices exist across different public health institutions in Mexico.
Purpose of the Study:
- To provide updated, relevant information on MPN diagnosis and treatment to healthcare professionals.
- To unify diagnostic and treatment criteria for myeloproliferative diseases nationwide.
- To enhance the quality of care for MPN patients across the Mexican Republic.
Main Methods:
- Inter-institutional consensus development.
- Review of current clinical practice guidelines and evidence.
- Expert panel discussions and agreement on recommendations.
Main Results:
- A unified set of recommendations for the diagnosis of MPNs.
- Standardized treatment protocols for various myeloproliferative diseases.
- Dissemination of consensus guidelines to public health institutions.
Conclusions:
- The consensus provides a crucial resource for healthcare professionals managing MPNs.
- Standardization of care is expected to improve patient outcomes in Mexico.
- This initiative promotes evidence-based practice in hematologic oncology.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
28
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
28
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
01:21Lineage Commitment
3.0K
Commitment is the process whereby stem cells:
3.0K
01:22Bone Marrow Sampling and Transplants
352
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
352
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K